Universitätsklinikum Würzburg 

ZIM (Zentrum Innere Medizin)
Haus A3/A4 

Oberdürrbacherstr. 6

97080 Würzburg


Publikationen 2012

S. Zeuzem, P. Buggisch, K. Agarwal, P. Marcellin, D. Sereni, H. Klinker, C. Moreno, J. P. Zarski, Y. Horsmans, H. Mo, S. Arterburn, S. Knox, D. Oldach,J. G.  McHutchison, M. P. Manns, G. R. Foster
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Hepatology. 2012; 55:749-58. doi: 10.1002/hep.24744
Impact Factor: 12.003

C. Sarrazin, T. Berg, M. Cornberg, M. Dollinger, P. Ferenci, H. Hinrichsen, H. Klinker, M. Kraus, M. Manns, S. Mauss, M. Peck-Radosavljevic, H. Schmidt, U. Spengler, H. Wedemeyer, S. Wirth, S. Zeuzem
Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C
Z Gastroenterol. 2012;50:57-72. doi: 10.1055/s-0031-1282015. Epub 2012 Jan 5
Impact Factor: 1.408

C. Kasang, A. Ulmer, N. Donhauser, B. Schmidt, A. Stich, H. Klinker, S. Kalluvya, E. Koutsilieri, A. Rethwilm, C. Scheller
HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients
BMC Infect Dis. 2012 12:14. doi: 10.1186/1471-2334-12-14
Impact Factor: 3.025

W. J. Heinz, A. Grau, A. Ulrich, A. Helle-Beyersdorf, J. Zirkel, D. Schirmer, U. Lenker, H. Einsele, H. Klinker
Impact of benzodiazepines on posaconazole serum concentrations. A population-based pharmacokinetic study on drug interaction.
Curr Med Res Opin. 2012 28:551-7. doi: 10.1185/03007995.2012.664123. Epub 2012 Feb 28
Impact Factor: 2.263

A. Helle-Beyersdorf, J. Zirkel, A. Heidemeier, H. Klinker, W. J. Heinz
Tuberculosis as a rare cause for an abdominal mass: report on three cases and review of the literature
Z Gastroenterol. 2012 50:288-92. doi: 10.1055/s-0031-1282000. Epub 2012 Mar 1
Impact Factor: 1.408

D. Burger, D. Back, P. Buggisch, M. Buti, A. Craxí, G. Foster, H. Klinker, D. Larrey, I. Nikitin, S. Pol, M. Puoti, M. Romero-Gómez, H. Wedemeyer, S. Zeuzem
Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.
J Hepatol. 2012 Nov 5. pii: S0168-8278(12)00828-8. doi: 10.1016/j.jhep.2012.10.027. [Epub ahead of print]
Impact Factor: 9.858

S. Innes, E. Schulte-Kemna, M. F. Cotton, E. W. Zöllner, R. Haubrich, H. Klinker, X. Sun, S. Jain, C. Edson, M. van Niekerk, E. R. Innes, H. Rabie, S. H. Browne
Biceps Skin-Fold Thickness May Detect and Predict Early Lipoatrophy in HIV-Infected Children.
Pediatr Infect Dis J. 2012 Dec 17. [Epub ahead of print]
Impact Factor: 3.569

G. Maschmeyer, W. J. Heinz, B. Hertenstein, H. A. Horst, C. Requadt, T. Wagner, O. A. Cornely, J. Löffler, M. Ruhnke on behalf of the IDEA study investigators
Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study.
Eur J Clin Microbiol Infect Dis. 2012 Dec 28. [Epub ahead of print]
Impact Factor: 3.024

W. J. Heinz, G. Egerer, H. Lellek, A. Boehme, J. Greiner
Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis.
Mycoses. 2012 Nov 21. [Epub ahead of print]
Impact Factor: 1.278

M. Reinwald, M. Hummel, E. Kovalevskaya, Spiess B, W. Heinz W,  J. J. Vehreschild, B. Schultheis, S. W. Krause, B. Claus, T. Suedhoff, Schwerdtfeger R, Reuter S, Kiehl MG, Hofmann WK, Buchheidt D.
Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies.
J Antimicrob Chemother 2012; Sep;67(9):2260-7. doi: 10.1093/jac/dks208. Epub 2012 Jun 27
Impact Factor: 5.338

M. Reinwald, B. Spiess, W. J. Heinz, J. J. Vehreschild, C. Lass-Floerl, M. Kiehl, B. Schultheis, S. W. Krause, H. H. Wolf, H. Bertz, G. Maschmeyer, W. K. Hofmann, D. Buchheidt
Diagnosing Pulmonary Aspergillosis in Patients with Hematological Malignancies:A Multicenter Prospective Evaluation of an Aspergillus PCR assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples.
Eur J Haematol. 2012 Jun 1. [Epub ahead of print]
Impact Factor: 2.548

F. Weissinger, H. W. Auner, H. Bertz, D. Buchheidt, O. A. Cornely, G. Egerer, W. Heinz, M. Karthaus, M. Kiehl,W.  Krüger, O. Penack, S. Reuter, M. Ruhnke, M. Sandherr, H. J. Salwender, A. J. Ullmann, D. T. Waldschmidt, H. H. Wolf
Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Ann Hematol. 2012 May 26. [Epub ahead of print]
Impact Factor: 2.866

J. Springer, H. Schloßnagel, W. Heinz, T. Doedt, R. Soeller, H. Einsele, J. Loeffler.
A Novel Extraction Method Combining Plasma With Whole Blood Fraction Shows Excellent Sensitivity and Reproducibility in Patients at High Risk for Invasive Aspergillosis.
J Clin Microbiol. 2012 May 16. [Epub ahead of print]
Impact Factor: 4.068

O. A. Cornely, D. Helfgott, A. Langston, W. Heinz, J. J. Vehreschild, m. J. Vehreschild, G. Krishna, L. Ma, S. Huyck, M. C. McCarthy
Pharmacokinetics of Different Dosing Strategies of Oral Posaconazole in Patients With Compromised Gastrointestinal Function and Who Are at High Risk for Invasive Fungal Infection.
Antimicrob Agents Chemother. 2012: May;56(5):2652-8. doi: 10.1128/AAC.05937-11. Epub 2012 Jan 30
Impact Factor: 4.565

G. Wurthwein, C. Young, C. Lanvers-Kaminsky, G. Hempel, M. N. Trame, R. Schwerdtfeger, H. Ostermann, W. J. Heinz, O. A. Cornely, H. Kolve, J. Boos, G. Silling, A. H. Groll
Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.
Antimicrob Agents Chemother. 2012 Jan;56(1):536-43
Impact Factor: 4.565

J. Zirkel, H. Klinker, A. Kuhn, M. Abele-Horn, D. Tappe, D. Turnwald, H. Einsele, W. Heinz 
Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors.
Med Mycol. 2012 Jan;50(1):50-5.
Impact Factor: 1.979

H. Klinker
Drug-Interaktionen bei den HCV Protease-Inhibitoren
MedReport 9/2012, 8

C. Kasang, S. Kalluvya, C. Majinge, A. Stich, J. Bodem, G. Kongola, G. B. Jacobs, M.
Mllewa, M. Mildner, I. Hensel, A. Horn, W. Preiser, G. van Zyl, H. Klinker, E. Koutsilieri,   
A. Rethwilm, C. Scheller, B. Weissbrich
HIV drug resistance (HIVDR) in Tanzania is dramatically higher than estimated by WHO treshold HIVDR survey
22nd Annual Meeting of the Society for Virology, Essen 14-17 March 2012, Abstract  0391

H. Klinker
Drug-Interaktionen bei den HCV-Protease Inhibitoren
In: HIV/AIDS, Hepatitis, Infektiologie 2012, Hrsg. C. Hoffmann, H. Jäger, Blackwell-Verlag GmbH, Berlin, S. 39

W. Heinz, A. Grau, A. Helle-Beyersdorf, J. Zirkel, D. Schirmer, U. Lenker, H. Klinker
Interaktionspotential von Benzodiazepinen auf Serumspiegel von Posaconazol
11. Kongress für Infektionskrankheiten und Tropenmedizin (KIT), 25.-28.04.2012, Köln, P57       Posterpreis

H. Klinker
Medikamentenwechselwirkungen in der Proteaseinhibitor-Therapie der HCV-Infektion
11. Kongress für Infektionskrankheiten und Tropenmedizin (KIT), 25.-28.04.2012, Köln, P60

J. Zirkel, W. Heinz, S. Kleinert, A. Helle-Beyersdorf, H. Klinker      
Kasuistik: Hochfieberhafte Lymphadenopathie
11. Kongress für Infektionskrankheiten und Tropenmedizin (KIT), 25.-28.04.2012, Köln, P82

H. Klinker
Medikamenten-Interaktionen in der Hepatologie
HepNet Journal/Deutsche Leberstiftung 2012; 6: Ausgabe 1, S. 6-7

J. Vermehren, J. Lötsch, H. Klinker, S. Susser, A. Doehring, S. Zeuzem, C. Sarrazin
Protection against anemia by ITPA gene variants is dependent on ribavirin (RBV) serum concentrations during antiviral therapy for HCV genotype 1 infection
63th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 09. - 13.11.2012, Boston, Abstract 1739, Hepatology 2012; 54 (Suppl): 1002A

J. Fischer, S. Böhm, D. Deichsel, V. Knop, H. Klinker, B. Möller, J. rasenack, H. Hinrichsen, U. Spengler, P. Buggisch, C. Sarrazin, T. Berg
Associations of genetic variants of mitochondrial antiviral signaling protein (MAVS), interferon regaulatory factor 7 (IRF7) and Toll-like receptor 3 (TLR3) with interferon response in Hepatitis C virus infection
63th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 09. - 13.11.2012, Boston, Abstract 1770, Hepatology 2012; 54 (Suppl): 1018A

G. Grammatikos, S. Susser, S. Schwendy, N. Dikopoulos, P. Buggisch, J. Encke, G. teuber, T.  Goeser, R. Thimme, H. Klinker, W. O. Boecher, E. Ramos-Lopez, K. Badenhoop, E. Schulte-Frohlinde, S. Zeuzem, T. Berg, C. Sarrazin
Variations in the levels of IP10 but not of vitamin D during Interferon-based antiviral therapy are able to predict virologic response rates in a large well characterized cohort of patients with genotype 1 chronic Hepatitis C infection
63th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 09. - 13.11.2012, Boston, Abstract 1815, Hepatology 2012; 56 (Suppl): 1039A

M. Backmund, N. Forestier, K. Isernhagen, H. Klinker, U. Naumann, J. Reimer, G. Teuber, W. Tietje
Aktuelle Aspekte zur HCV-Triple-Therapie bei Suchtpatienten
Suchtmedizin in Forschung und Praxis 2012; 14: 265-271